China is to get its first access to an automatic screening system for genetic disorders in embryos after the CFDA cleared PerkinElmer's ($PKI) Genetic Screening Processor system, according to the U.S.-based company.
The maker of medical devices, with offices in Shanghai, said the screening system works with its reagent kit to analyze tests of neonatal dried-blood samples to detect disorders, including for congenital hypothyroidism.
PerkinElmer said the device was capable of testing for a wide range of disorders on a single platform. It said it also planned to introduce other GSP assays to China.
- here's the PerkinElmer release